Predicting potentially pathogenic effects of h RPE65 missense mutations: a computational strategy based on molecular dynamics simulations.
Giulio PoliIvana BarravecchiaGian Carlo DemontisAndrea SodiAlessandro SabaStanislao RizzoMarco MacchiaTiziano TuccinardiPublished in: Journal of enzyme inhibition and medicinal chemistry (2022)
The human retinal pigment epithelium-specific 65-kDa protein ( h RPE65) plays a crucial role within the retinoid visual cycle and several mutations affecting either its expression level or its enzymatic function are associated with inherited retinal diseases such as Retinitis Pigmentosa. The gene therapy product voretigene neparvovec (Luxturna) has been recently approved for treating hereditary retinal dystrophies; however, the treatment is currently accessible only to patients presenting confirmed biallelic mutations that severely impair h RPE65 function, and many reported h RPE65 missense mutations lack sufficient evidences for proving their pathogenicity. In this context, we developed a computational approach aimed at evaluating the potential pathogenic effect of h RPE65 missense variants located on the dimerisation domain of the protein. The protocol evaluates how mutations may affect folding and conformation stability of this protein region, potentially helping clinicians to evaluate the eligibility for gene therapy of patients diagnosed with this type of h RPE65 variant of uncertain significance.
Keyphrases
- gene therapy
- molecular dynamics simulations
- end stage renal disease
- intellectual disability
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- endothelial cells
- diabetic retinopathy
- gene expression
- binding protein
- poor prognosis
- amino acid
- dna methylation
- patient reported outcomes
- nitric oxide
- palliative care
- climate change
- autism spectrum disorder
- copy number